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| INTRODUCTION
Psoriasis is a common inflammatory skin disease with high prevalence in most industrialized countries. [1] Individuals with psoriasis have thickened, sharply demarcated, erythematous plaques with silver scales [2] and have an increased risk of developing comorbidities such as psoriatic arthritis, Crohn's disease, depression, cardiovascular disease and metabolic syndrome. [3] The aetiology of psoriasis is not entirely understood although genetic susceptibility [4] and environmental stimuli [5] are important factors contributing to the pathogenesis of this condition.
Psoriasis is one of the most prevalent T-cell-mediated diseases. [6] The effectiveness of immune-modulating medications [6] [7] [8] for the treatment of psoriasis underscores the vital role of the immune system and the aberrant adaptive and innate immune responses in psoriasis pathogenesis. Psoriasis has primarily been classified as an immunemediated inflammatory disorder rather than an autoimmune condition [9] largely due to the fact that no convincing autoantigens had previously been identified. Recently, three psoriasis autoantigens have been reported to be involved in the pathogenesis of psoriasis, namely cathelicidin (LL37), [10] a disintegrin and metalloprotease domain containing thrombospondin type 1 motif-like 5 (ADAMTSL5), [11] and lipid antigens generated by phospholipase A2 group IVD (PLA2G4D). [12] LL37, a keratinocyte-derived antimicrobial peptide overexpressed in psoriatic skin, is a 37 amino acid cationic peptide produced from the extracellular cleavage of the C-terminal end of the 18 kDa hCAP18 protein in keratinocytes [13] and neutrophils. [14] LL37 is upregulated in psoriatic lesions and has been shown to contribute to psoriasis pathogenesis primarily through the activation of dendritic cells (DCs), which subsequently promote the activation and expansion of pathogenic T cells. [10, 15, 16] A recent study also reported the increased expression of a novel cytosolic phospholipase A2 lipid antigen, PLA2G4D, in psoriatic lesions. [12] PLA2G4D was observed to be expressed in psoriatic keratinocytes and mast cells and generates lipid antigens that are recognized by CD1a-restricted T cells, thereby inducing the production of IL-22 and IL-17A. [12] Lastly, ADAMTSL5 is a novel protein that is secreted and shown to bind to fibrillin-1 and fibrillin-2 and could play a role in modulating microfibril functions. [17] In psoriasis, ADAMTSL5
was found to be presented by HLA-C*06:02-restricted melanocytes that activate IL-17-producing T cells. [11] We recently described the diffuse distribution of ADAMTSL5 in lesional and non-lesional psoriatic skin by immunohistochemistry, including its expression in keratinocytes and unidentified dermal cells. [18] In this present study, we sought out to describe the expression of ADAMTSL5 and LL37 in lesional and non-lesional psoriatic skin, 
| METHODS

| Patient characteristics
Lesional, non-lesional and post-treatment (n=10) skin biopsies were obtained from patients with moderate-to-severe psoriasis under IRB-approved protocols. Informed consent was obtained and the study was performed in adherence with the Declaration of Helsinki Principles.
| Immunohistochemistry (IHC) and immunofluorescence (IF)
Standard procedures were used for IHC and IF as previously described. [19] Table S1 .
Histological images were acquired using the appropriate fil- 
| Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR)
RNA was extracted from lesional, non-lesional and post-treatment skin biopsies using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). qRT-PCR was performed using EZ PCR core reagents, primers and probes (Life Technologies, Grand Island, NY, USA) as previously published. [19] Sequences of primers and probes used in this study are found in Table   S1 . The results were normalized to the hARP housekeeping gene.
| Microarray
The data discussed in this publication have been previously published and deposited in the Gene Expression Omnibus of the National Center for Biotechnology Information and are accessible through its series accession number GSE11903 for the etanercept Study, GSE31652 for the ixekizumab Study and GSE53552 for the brodalumab Study.
| Statistical analysis
Means, changes from baseline and differences between groups for quantitative (cell counts) in IHC, Log-2 transformed qRT-PCR and gene expression from micro-array data were assessed estimating a mixed-effect model with fixed factors: time (baseline/post-treatment), tissue (LS/NL) and its interactions, considering random intercept for each patient. P values from the t tests were adjusted for multiple hypotheses using the Benjamini-Hochberg procedure. The analysis was performed using linear mixed-effects (nlme) [20] and least-squares means (Lsmeans) R packages. [21] 3 | RESULTS
| Distribution and expression pattern of ADAMTSL5 and LL37
We performed immunohistochemistry staining of ADAMTSL5 and LL37 on lesional and non-lesional psoriasis tissues to determine the distribution and expression pattern of these antigens ( Figure 1 ). We observed that there was increased expression of both ADAMTSL5 and LL37 proteins in lesional compared to non-lesional skin ( Figure 1A ).
In agreement with previously published data, ADAMTSL5 was ex- 
| ADAMTSL5 and LL37 are co-expressed by specific dermal leukocytes
To determine which immune cells express the ADAMTSL5 and LL37
antigens, we performed two-colour immunofluorescence on nonlesional and lesional psoriasis skin with markers for dendritic cells Likewise, in both lesional and non-lesional skin, LL37 was coexpressed with many (~50%) CD11c + myeloid dendritic cells and BDCA1/CD1c + resident dendritic cells in the superficial dermis ( Figure 3A ,B), while those in the deeper dermis was co-expressed with many (~50%) CD163 + macrophages ( Figure 3C ). LL37 was also co-expressed with most (~75%) neutrophils ( Figure 3D ). But only a few (~15%) LL37 was co-expressed with CD3 + and CD8 + T cells in the dermal aggregates ( Figure 3E,F) . High expression of LL37 in neutrophils, but not lymphocytes (not shown), was confirmed by FACS staining of peripheral blood (Fig. S4 ).
| ADAMTSL5 and LL37 are decreased after treatment
To show the effect of treatment on ADAMTSL5 and LL37, we performed immunohistochemistry (IHC) staining and gene expression We also looked into the possibility that ADAMTSL5 and LL37 are IL-17-or TNF-α-regulated molecules, so we checked our microarray analysis data of patients treated with brodalumab, ixekizumab, adalimumab and etanercept ( Figure 4D-F) . In brodalumab-treated patients, we found significant (P<.05) upregulation of CAMP/LL37 in lesional skin compared to non-lesional skin and downregulation following treatment. We also noted upregulation of ADAMTSL5 in lesional skin and downregulation following treatment ( Figure 4D ).
In ixekizumab-treated patients, CAMP/LL37 was also downregulated in post-treatment lesional skin ( Figure 4E ). In both adalimumab-and etanercept-treated patients, there was significant (P<.01) upregulation of CAMP/LL37 in lesional skin compared to non-lesional skin and significant downregulation following treatment ( Figure 4F ).
| DISCUSSION
Psoriasis has been characterized as a T-cell-mediated disorder with a probable autoimmune pathogenesis due to the following:
(i) a strong association with the HLA-C*06:02 allele, the primary psoriasis susceptibility locus; (ii) the absence of an identified infectious agent or exogenous antigen that triggers the development of disease and (iii) the clinical efficacy of immunomodulatory agents directed against T cells. [22] Recently, multiple studies have described several autoantigens involved in the pathogenesis of psoriasis including LL37, [10] ADAMTSL5 [11] and lipid antigens generated by PLA2G4D, [12] thus suggesting psoriasis is an autoimmune disease.
Our group recently published the cutaneous expression of ADAMTSL5 in psoriatic lesional and non-lesional skin and showed that this antigen is not only expressed by melanocytes, but also by keratinocytes and discrete but undefined dermal immune cells near the DEJ and in the superficial and deep dermis. [18] In this present study, we show that LL37 is also widely expressed in keratinocytes and many may present these antigens to autoreactive Th17 cells with ensuing activation and clonal expansion. [23] Cathelicidins are a gene family that are known for their antimicrobial action. The human cathelicidin peptide, LL37, is a keratinocytederived antimicrobial peptide that is strongly expressed in the epidermis and dermis of lesional psoriatic skin. [15] In response to skin trauma or viral/bacterial infections, LL37 forms complexes with extracellular self-nucleic acids and promotes loss of immune tolerance through the stimulation of endosomal TLR-7/9 and TLR-8 in plasmacytoid (pDC) and myeloid (mDC) dendritic cells, respectively. [15, 16] A similar mechanism of pDC activation has been described for hBD2, hBD3 and lysozyme. [24] The activation of pDCs and mDCs subsequently promotes the expansion of T cells that produce IFN-γ and Th17 cytokines. [10] Morizane et al. [25] showed that keratinocytes from psoriatic skin have increased levels of LL37 and toll-like receptor (TLR)-9, and the sequential addition of LL37 and CpG DNA enhanced TLR-9 responsiveness and type I interferon (IFN) expression.
LL37 in the presence of RNA also enhances type I IFN responses in a TLR3-dependent manner, [26] which may further promote the activation of mDCs. [27] A recent study showed that LL37 was recognized as an autoantigen by circulating T cells in up to 75% of patients with moderate-to-severe psoriasis and triggers activation of innate immune cells. [10] In macrophages, LL37 promotes cell differentiation towards a proinflammatory signature. In one study, monocytes cultured with M-CSF in the presence of LL37 resulted in a proinflammatory macrophage differentiation, while the peptide also enhanced the GM-CSF-driven macrophage differentiation. [28] LL37 was reported to be internalized by human macrophages through the P2X 7 receptor and the LL37/P2X 7 R complex is associated with clathrin-mediated endocytosis. [29] Taken together, the primary mechanisms by which LL37 appears to contribute to the development of psoriasis is (i) through the early stimulation of pathogenic immune cells, specifically the pDC and mDC populations, [15, 16] (ii) enhanced cytokine signalling in keratinocytes [25, 26] and (iii) by serving as an autoantigen for the activation of IFN-γ and Th17-producing T cells. [10] Another group identified ADAMTSL5 as an autoantigen for IL-17-producing CD8 + T cells in psoriasis when presented by HLA-C*06:02. [14] ADAMTSL5, a novel protein reportedly produced by melanocytes, was discovered in the late 2000s and appears to be important for microfibril function. [11] This protein may be distributed on epithelial cells and connective tissues during mouse embryonic development and localized on the pericellular and subcellular extracellular matrix of cells. [17] ADAMTSL5 may be an intracellular antigen in keratinocytes or dermal connective tissue cells or an extracellular deposition and it may trigger the reactivity of immune cells such as dendritic cells and macrophages. [23] The mechanism by which the antigen is taken up by immune cells is still not yet understood.
It is interesting to note that both LL37 and ADAMTSL5 are directly or indirectly regulated by IL-17. [22] IL-17 increases transcription of LL37 and induces the production of CXCL1 (a chemokine that was first identified as a melanocyte growth factor), which could stimulate melanocytes for ADAMTSL5 expansion in psoriatic lesions. [23] By FACS analysis, we found that LL37 was strongly expressed in circulating neutrophils, but not highly expressed by monocytes or lymphocytes. However, past studies have found some level of LL37 expression within mononuclear leukocyte populations using immunofluorescence microscopy and some leukocytes increase LL37 expression in response to exogenous cytokines. [30] Thus, some expression of LL37 in active The association between PLA2G4D and psoriasis is significant for several reasons. First, PLA2G4D is a novel PLA 2 enzyme that is absent in normal, healthy skin. [31] Second, its expression along with PLA 2 activity is increased in psoriatic skin lesions. [32] Third, the increased PLA2G4D expression in mast cells and keratinocytes results in the generation of non-peptide, lipid antigens that are recognized by CD1a-restricted T cells, which produce high amounts of Th-1 and Th-17 cytokines. [12] These findings provide evidence for the potential role of non-peptide antigens in the pathogenesis of psoriasis, which could explain why subsets of psoriasis patients lack LL37 or ADAMTSL5-specific T cells. Unfortunately, these lipid antigens are more difficult to characterize since they cannot be stained using traditional immunohistochemical antibodies-one limitation of our present study. In comparison to LL37 and ADAMTSL5, the neolipid antigens produced by PLA2G4D are largely understudied despite increased numbers of CD1a-reactive T cells found in the blood of normal subjects. [33] Interestingly, CD1a-reactive T cells are also cutaneous lymphocyte 
